Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Tvardi Therapeutics (TVRD) Non Operating Income (2016 - 2025)

Tvardi Therapeutics' Non Operating Income history spans 11 years, with the latest figure at $12.7 million for Q2 2025.

  • On a quarterly basis, Non Operating Income rose 1737.3% to $12.7 million in Q2 2025 year-over-year; TTM through Dec 2025 was $13.0 million, a 738.49% increase, with the full-year FY2025 number at $7.2 million, up 451.45% from a year prior.
  • Non Operating Income hit $12.7 million in Q2 2025 for Tvardi Therapeutics, up from $347000.0 in the prior quarter.
  • Over the last five years, Non Operating Income for TVRD hit a ceiling of $12.7 million in Q2 2025 and a floor of -$4.4 million in Q4 2024.
  • Historically, Non Operating Income has averaged $958777.8 across 5 years, with a median of $677000.0 in 2022.
  • Biggest five-year swings in Non Operating Income: plummeted 608.47% in 2024 and later soared 1737.3% in 2025.
  • Tracing TVRD's Non Operating Income over 5 years: stood at $140000.0 in 2021, then soared by 591.43% to $968000.0 in 2022, then fell by 9.71% to $874000.0 in 2023, then plummeted by 608.47% to -$4.4 million in 2024, then surged by 384.86% to $12.7 million in 2025.
  • Business Quant data shows Non Operating Income for TVRD at $12.7 million in Q2 2025, $347000.0 in Q1 2025, and -$4.4 million in Q4 2024.